Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 989 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diseases of the Musculoskeletal System and Connective Tissue Clear all
Completed Phase 2 Interventional

Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies

NCT00001261
View directory record Official record
Conditions
Dermatomyositis, Inclusion Body Myositis, Polymyositis
Interventions
Gamma Globulin
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 5:09 PM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

NCT01519791
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol, Placebo, Methotrexate
Biological · Other
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
70
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 30, 2026, 5:09 PM EDT
Completed Phase 3 Interventional Results available

A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).

NCT02222493
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PF-06438179, Infliximab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
43
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 30, 2026, 5:09 PM EDT
Completed No phase listed Observational Results available

A Study to Learn About the Study Medicine (Called Tofacitinib) in People With Psoriatic Arthritis

NCT05195814
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 30, 2026, 5:09 PM EDT
Completed Phase 1 Interventional

A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis

NCT05252533
View directory record Official record
Conditions
Juvenile Psoriatic Arthritis, Psoriasis, Arthritis, Juvenile
Interventions
Ustekinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
5 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Huntington Beach, California • Los Angeles, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 30, 2026, 5:09 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578
View directory record Official record
Conditions
Progressive Pulmonary Fibrosis
Interventions
BMS-986278, BMS-986278 Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years and older
Enrollment
1,057 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
81
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 70 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 30, 2026, 5:09 PM EDT
Completed Phase 3 Interventional Results available

Effects of Abatacept in Patients With Early Rheumatoid Arthritis

NCT02504268
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Methotrexate, Abatacept Placebo, Methotrexate Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
42
States / cities
Huntsville, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 30, 2026, 5:09 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

NCT06104124
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Dazodalibep, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
37
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone

NCT02066389
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Hemet, California • DeBary, Florida • Venice, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 30, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

NCT01643850
View directory record Official record
Conditions
Pigmented Villonodular Synovitis, PVNS, Giant Cell Tumor of the Tendon Sheath, GCCTS, Tenosynovial Giant Cell Tumor Localized or Diffused Type, GCTS
Interventions
MCS110, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 30, 2026, 5:09 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

NCT04223635
View directory record Official record
Conditions
Moderate Hepatic Impairment
Interventions
Pexidartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 30, 2026, 5:09 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis

NCT00221000
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methoxsalen, Extracorporeal Photopheresis
Drug · Procedure
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
10
States / cities
Westminister, Maryland • Worchester, Massachusetts • Morristown, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 30, 2026, 5:09 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia

NCT02436096
View directory record Official record
Conditions
Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases, Musculoskeletal Diseases, Nervous System Diseases, Neuromuscular Diseases, Rheumatic Diseases
Interventions
TNX-102 SL Tablet, 2.8mg, Placebo SL Tablet
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 30, 2026, 5:09 PM EDT
Active, not recruiting No phase listed Observational

A Global Clinical Study Investigating the Safety and Effectiveness of Smith and Nephew's Porous Knee System in Patients Who Need a Total Knee Replacement Due to Degenerative Arthritis, Post-traumatic Arthritis or Inflammatory Arthritis

NCT05197036
View directory record Official record
Conditions
Osteoarthritis, Post-traumatic Arthritis, Rheumatoid Arthritis
Interventions
Total Knee Arthroplasty
Procedure
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
12
States / cities
Atlanta, Georgia • Boston, Massachusetts • Novi, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 30, 2026, 5:09 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis

NCT01044498
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Ortho-Novum® 1/35
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 44 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
6
States / cities
Little Rock, Arkansas • Beverly Hills, California • Ormond Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2013 · Synced Oct 30, 2026, 5:09 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time

NCT01223365
View directory record Official record
Conditions
Chronic Pain
Interventions
Hydrocodone ER
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
54
States / cities
Mobile, Alabama • Anaheim, California • Beverly Hills, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 30, 2026, 5:09 PM EDT
Recruiting No phase listed Observational

A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

NCT04635111
View directory record Official record
Conditions
Hepatotoxicity, Tenosynovial Giant Cell Tumor
Interventions
TURALIO™
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
8
States / cities
Santa Monica, California • Whittier, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 30, 2026, 5:09 PM EDT
Completed No phase listed Observational

Prospective Study Measuring Clinical Outcomes of Knee Arthroplasty Using the VERASENSE™ Knee System

NCT01469299
View directory record Official record
Conditions
Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis, Post-traumatic Arthritis
Interventions
Not listed
Lead sponsor
Orthosensor, Inc.
Industry
Eligibility
50 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
8
States / cities
St. Helena, California • Fort Lauderdale, Florida • Naples, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 30, 2026, 5:09 PM EDT
Completed Phase 1 Interventional

A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis

NCT01904292
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year to 17 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
11
States / cities
Little Rock, Arkansas • Hartford, Connecticut • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 30, 2026, 5:09 PM EDT
Terminated Phase 1 Interventional

A Study to Evaluate Camoteskimab in Participants With Still's Disease

NCT04752371
View directory record Official record
Conditions
Adult Onset Still's Disease
Interventions
Camoteskimab (CERC-007, AVTX-007, AEVI-007)
Drug
Lead sponsor
Apollo Therapeutics Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Gainesville, Florida • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 30, 2026, 5:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers

NCT01358383
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
naproxen, esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 30, 2026, 5:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of a 16-Week Individualized, Intensive Strength Training Program in Patients With Rheumatoid Arthritis

NCT00327275
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
strength training
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 18, 2006 · Synced Oct 30, 2026, 5:09 PM EDT
Completed Phase 3 Interventional Results available

Collagenase in the Treatment of Dupuytrens Disease

NCT00260429
View directory record Official record
Conditions
Dupuytren's Disease
Interventions
collagenase clostridium histolyticum
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2010 · Synced Oct 30, 2026, 5:09 PM EDT
Completed Phase 1 Interventional

A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)

NCT02614716
View directory record Official record
Conditions
Sjögren's Syndrome
Interventions
LY3090106, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Baltimore, Maryland • Albuquerque, New Mexico • Concord, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 30, 2026, 5:09 PM EDT